Management for Universal Detection Technology (UDTT.OB) Covers Broad Spectrum of Experience and Knowledge
Universal Detection Technology (OTCBB: UDTT) is engaged in the development of technologies which can be used to defend against bioterrorism by U.S. and regional homeland security forces. The company has established a partnership with NASA’s Jet Propulsion Laboratory and is backed by a management team with the technical expertise and business acumen needed for success.
Jacques Tizabi, CEO and chairman of Universal Detection, actively serves as a public speaker and board member to private and public companies in an array of sectors including medical devices, information technology, diversified entertainment and international business development. Tizabi has taken part in several local, state and federal political campaigns, and holds a Bachelor of Science from New York University’s Stern School of Business. He also holds a Master of Business Administration from Pepperdine University.
Acting as scientific liaison between Universal Detection and NASA’s Jet Propulsion Laboratory, Amir Ettehadieh plays an integral role in the development of the company’s bio-detection devices. Ettehadieh was previously an environmental scientist for environmental consulting firm EMG; oversaw site inspections for more than 150 hazardous material sites and their impacts on the environment; and holds a Bachelor of Art in biology.
Nima Montazeri oversees Universal Detection’s finance and strategic developments, and is responsible for the creation and implementation of the company’s goals, decisions, alliances and visions. Montazeri’s resume includes experience in corporate finance, global expansion and management consulting. He holds a Bachelor of Arts in economics with honors from the University of British Columbia and a master’s degree in finance and accounting from the London School of Economics.
Ali Moussavi’s previous experience in global business expansion assists in his direction of Universal Detection’s international collaborations, and his oversight enables the company to move into wider opportunities in global markets. Moussavi previously served as corporate advisor to numerous companies, structuring financial and business reorganization plans for each. He has experience in investment/database expansion for both U.S. and European companies and organizations. Moussavi holds a Bachelor of Arts from New York University in mathematics.
As chairman of the scientific advisory board, Dr. Louis J. Ignarro’s previous achievements include winning the Nobel Prize for Physiology or Medicine in 1998 for his research on nitric oxide. Dr. Ignarro served as professor of pharmacology for UCLA’s School of Medicine (Los Angeles) and Tulane University’s School of Medicine (New Orleans). Prior to teaching, Dr. Ignarro worked as a scientist at CIBA-GEIGY and has published articles which earned him the Basic Research Prize of the American Heart Association for his contributions to cardiovascular science. He holds a Bachelor of Science in pharmacology from Columbia University, a Ph.D. in pharmacology from the University of Minnesota, and his Postdoctoral Fellowship from the National Institutes of Health.
Dr. Leonard Makowka serves on Universal Detection’s scientific advisory board. His previous accomplishments include positions in several executive positions. Dr. Makowka was founder, and previously executive director, of the Comprehensive Liver Disease and Treatment Center at St. Vincent Medical Center in Los Angeles, CA; and has also served as the chairman of the Department of Surgery, director of Transplantation Services at Cedars-Sinai Medical Center in Los Angeles, CA. Dr. Makowka holds a Bachelor of Medicine from the University of Toronto Medical School, a Master of Science, and Doctorate of Philosophy from the University of Toronto ’s Department of Pathology. He has authored and published more than 400 articles based on clinical and scientific research. Additionally, Dr. Makowka has performed hundreds of hepatobiliary and liver transplant procedures.
Dr. Adrian Ponce, California Institute of Technology’s (CALTECH’s) visiting associate in Chemistry and Senior Technical Staff Member at JPL, currently serves as chairman of JPL’s Chemical Safety Committee and is an active member of the JPL Science Advisory Council. Dr. Ponce holds a Ph.D. in chemistry from the California Institute of Technology and a Bachelor of Science in chemistry from Michigan State University.
Please see disclaimer on QualityStocks.net website: http://Disclaimer.QualityStocks.net
$0.0006 (03/25/08)
